You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Review: long acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease

Article Text

Article menu
Download PDFPDF
Therapeutics
Review: long acting β2-agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease

https://doi.org/10.1136/ebm.9.3.79

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Sin DD, McAlister FA, Man SF, et al. Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 2003;290:2301–12.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q What are the effects of common treatments for chronic obstructive pulmonary disease (COPD) on patient outcomes?

    Clinical impact ratings GP/FP/Primary care ★★★★★☆☆ IM/Ambulatory care ★★★★★☆☆ Internal medicine ★★★★★☆☆ Respirology ★★★★★☆☆

    METHODS

    Embedded ImageData sources:

    Medline (1980 to 1 May 2002), Cochrane Database of Systematic Reviews, bibliographies of published articles, and experts.

    Embedded ImageStudy selection and assessment:

    English language randomised controlled trials with ⩾3 months of follow up in adults with COPD that assessed long acting (LA) β2 agonists (β2As); LA inhaled anticholinergics (tiotropium); combined short acting (SA) β2As and SA anticholinergics; inhaled corticosteroids; combined inhaled corticosteroids and LAβ2As; pulmonary rehabilitation (with ⩾6 wks follow up); long term nocturnal non-invasive mechanical ventilation; domiciliary O2 therapy; or disease management. Analysis …

    View Full Text

    Footnotes

    • ↵* Information provided by author.

    • For correspondence: Dr D D Sin, James Hogg iCAPTURE Center for Pulmonary and Cardiovascular Research, Vancouver, British Columbia, Canada. dsinmrl.ubc.ca

    • Sources of funding: Canadian Institutes of Health Research and Alberta Heritage Foundation for Medical Research.